Upstream Bio Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Upstream Bio Inc
Access all reports
Upstream Bio Inc. is a U.S.-based biotechnology company focused on developing innovative therapies for inflammatory and allergic diseases. The company’s research is centered on targeting key biological pathways involved in immune response, with the goal of creating treatments that address unmet medical needs in conditions such as asthma and other chronic inflammatory disorders. Upstream Bio’s pipeline includes investigational drugs aimed at modulating immune mechanisms to improve patient outcomes and quality of life. Upstream Bio Inc. is headquartered in Waltham, Massachusetts.
Latest articles
What Investors Get Wrong: Chris Mayer on Dividends, Noise, and the Power of Reinvestment
Chris Mayer challenges investor myths on dividends, market noise, and the reinvestment edge. A deep dive into long-term thinking.
29 Nov 2024
Evolution: The Live Casino Juggernaut
With ~49% CAGR since its 2015 IPO, 60%+ EBIT margin, and global dominance in live casino, the story of Evolution is truly one for the books.
22 Nov 2024
House of Warhammer: The Inner Workings of Games Workshop
A look under the hood of Games Workshop, a high-margin business in an incredibly niche market, with sky-high stock returns.
15 Nov 2024
Ticker symbol
UPB
Country
🇺🇸 United States